X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.globenewswire.com/news-release/2023/01/12/2587573/0/en/Roche-announces-the-European-Commission-approval-of-Xofluza-for-the-treatment-and-prevention-of-influenza-in-children-aged-one-year-and-above.html
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-baloxavir-marboxil-tablets-55892.pdf
https://www.usnews.com/news/top-news/articles/2022-08-12/roche-gets-u-s-approval-for-flu-drug-for-children-aged-5-and-over
https://www.fiercepharma.com/pharma/merck-molnupiravir-blockbuster-covid-19-pandemic-endemic-oral-antivirals-market
https://www.reuters.com/article/us-roche-xofluza/roche-gets-eu-green-light-for-influenza-treatment-xofluza-idUSKBN29G0EZ
https://www.fiercepharma.com/marketing/roche-s-xofluza-wins-fda-nod-to-prevent-flu-but-hits-a-snag-bid-to-reach-younger-patients
https://www.fda.gov/news-events/press-announcements/fda-expands-approval-influenza-treatment-post-exposure-prevention
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2020
https://www.financialexpress.com/industry/cipla-to-manufacture-anti-viral-drugs-eyeing-covid-containment/1902628/
https://cen.acs.org/sections/coronavirus/biological-chemistry/infectious-disease/coronavirus-drug-repurposing.html
https://www.fiercepharma.com/pharma/roche-s-flu-med-xofluza-drives-drug-resistance-and-may-be-a-bad-choice-for-kids-study-says
https://www.prnewswire.com/news-releases/genentech-makers-of-new-flu-treatment-xofluza-baloxavir-marboxil-announces-partnership-with-virtual-health-platform-plushcare-300952890.html
https://www.fiercepharma.com/marketing/flattened-by-flu-roche-s-genentech-launches-first-consumer-campaign-for-xofluza
http://www.pharmatimes.com/news/xofluza_bags_fda_approval_for_flu_complications_1313767
https://www.fiercepharma.com/pharma/roche-s-tamiflu-follow-up-xofluza-beat-out-placebo-stopping-spread-flu-from-household
http://www.pharmatimes.com/news/xofluza_effective_as_preventative_flu_medicine_1300454
https://www.in-pharmatechnologist.com/Article/2019/08/05/Roche-divests-Tamiflu-rights-to-Sanofi
https://www.fiercepharma.com/pharma/xofluza-hand-roche-offloads-tamiflu-u-s-otc-switch-rights-to-sanofi
https://www.biospace.com/article/genentech-s-xofluza-comparable-to-tamiflu-in-phase-iii-trial/
https://www.fiercepharma.com/pharma/roche-s-xofluza-scores-trial-win-flu-prevention-providing-sales-hope-as-tamiflu-craters
https://www.businesswire.com/news/home/20190305006084/en/FDA-Accepts-Genentech%E2%80%99s-Supplemental-New-Drug-Application/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==
https://www.fiercepharma.com/pharma/will-mutant-strains-hurt-prospects-for-roche-s-flu-newcomer-xofluza
https://www.biospace.com/article/japan-s-love-for-genentech-s-xofluza-flu-treatment-may-be-waning/
https://blogs.sciencemag.org/pipeline/archives/2019/02/04/2018-drug-approvals-a-closer-look?r3f_986=https://www.google.com/
https://www.prnewswire.com/news-releases/viracor-eurofins-launches-baloxavir-marboxil-xofluza-influenza-a-antiviral-resistance-pcr-for-2019-flu-season-300789271.html
https://www.biospace.com/article/a-llama-antibody-could-be-the-key-to-a-universal-flu-vaccine/
http://www.pharmatimes.com/news/us_approves_first-in-class_flu_drug_1257430
https://www.reuters.com/article/us-shionogi-flu/shionogi-aims-to-double-flu-drug-market-with-fda-approved-treatment-idUSKCN1N319M
https://www.forbes.com/sites/brucelee/2018/10/25/fda-approves-xofluza-what-makes-this-new-flu-treatment-different/#43c94db6191f
https://www.reuters.com/article/us-roche-hldg-fda/fda-approves-first-new-flu-drug-in-almost-two-decades-idUSKCN1MY2JQ
https://www.news-medical.net/news/20181025/New-flu-drug-Xofluza-approved-FDA-emphasizes-importance-of-flu-shots.aspx
https://endpts.com/roches-new-single-pill-flu-drug-gets-the-green-light-at-a-hard-charging-fda-breaking-into-record-setting-territory/
https://endpts.com/roche-just-heralded-a-great-set-of-placebo-comparisons-for-their-new-flu-drug-too-bad-it-flopped-against-generic-tamiflu/
http://www.pharmatimes.com/news/roche_unveils_phiii_data_for_flu_drug_1254488
https://www.fiercepharma.com/pharma/roche-s-next-generation-flu-drug-beats-placebo-at-risk-patients-but-what-about-tamiflu
https://endpts.com/genentech-takes-aim-at-biogen-and-novartis-highlighting-an-early-look-at-positive-results-for-their-oral-sma-drug-from-ptc/
https://www.hhs.gov/about/news/2018/10/01/hhs-genentech-join-forces-medicines-combat-influenza-other-health-security-threats.html
https://endpts.com/roche-hands-over-another-batch-of-positive-phiii-data-on-its-new-flu-drug-looking-for-an-early-winter-launch/
http://www.pharmatimes.com/news/priority_review_for_genentechs_flu_drug_1242323
https://www.forbes.com/sites/brucelee/2018/02/24/japans-new-drug-one-pill-may-stop-the-flu-in-just-one-day/#3dc7e76c2b34
Market Place
Share 
